Myelodysplastic syndromes (MDS) are clonal stem cell disorders usually characterized by cytopenia and dysplasia. MDS are usually diagnosed during the sixth decade and are associated with reduced life expectancy, mainly related to transformation to acute leukemia, infections, or bleeding. Currently, the only potentially curative treatment for MDS is allogeneic hematopoietic stem cell transplantation (HSCT) [1] [2] [3] . However, HSCT is associated with significant morbidity and mortality mainly related to acute or chronic graft-vs.-host disease (aGvHD or cGvHD) [4, 5] . In the Geneva Stem Cell Transplant Center we use partial in vitro T-cell-depleted grafts usually for patients in complete remission at transplant to reduce GvHD incidence [6] . Indeed, partial T-cell depletion decreases the number of alloreactive donor T cells triggering GvHD. However, it is hypothesized that this strategy could increase relapse incidence (RI) and decrease overall survival (OS) due to the loss of the graft-vs.-leukemia effect mediated by donor lymphocytes. Impact of partial T-cell depletion was previously investigated in a cohort of patients, including heterogeneous diseases and results had shown no worsening of outcome for partially T-cell-depleted patients [7] . However, the impact of partial T-cell depletion was never specifically investigated for patients undergoing transplantation for MDS.
In this retrospective study, we investigated patients allografted for a diagnosis of MDS over a 19 years' period (from 01 January 1998 to 31 August 2016). Patients aged ≥18 years old at transplant time, who had a diagnosis of MDS according to the 2008 World Health Organization criteria, and who had a first HSCT were included. Patients with haploidentical transplantation, stem cell from identical twins, umbilical cord blood transplantation, or more than two human leukocyte antigen (HLA) loci-or allelemismatched unrelated donor (MMUD) transplantation were excluded. This study was approved by an ethics committee.
Primary outcomes were comparison of 3-year OS, progression-free survival (PFS), GvHD-free/relapse-free survival (GRFS) [8] , RI, and non-relapse mortality (NRM) between partially T-cell-depleted patients and non-T-celldepleted ones. Secondary outcomes were impact of partial T-cell depletion on grade 2-4 acute and chronic GvHD.
Sixty-two patients were included. Forty-four percent were female, median age at transplant was 48 years (range: 18-70 years) with myeloablative conditioning for 66% and reduced intensity for 34%. Median time from diagnosis to HSCT was 7.5 months (range: 3-86 months). Peripheral blood stem cell (90%) or bone marrow (BM; 10%) grafts were from HLA-identical siblings (45%), HLA-matched unrelated donor (MUD; 42%), or MMUD (13%). Antithymocyte globulin was used for 56% of patients and partial T-cell depletion was performed for 52% of patients. Median follow-up was 4.6 years (range: 0-15). Patients' characteristics and data on transplantation are shown in Table 1 .
Myeloablative conditioning usually consisted of cyclophosphamide (120 mg/kg) with either total body irradiation 2 ) with low-dose busulfan (8 mg/kg oral or 6.4 mg/kg intravenously) with or without rabbit antilymphocyte globulin. Partial T-cell depletion was performed using alemtuzumab (Campath [Genzyme Corporation, Cambridge, MA, USA]) "in the bag" as previously described [5] . T-celldepleted grafts were given on day + 0 followed by an addback (usually 100 × 10 6 donor T cells/kg) on day + 1. Baseline characteristics were descriptively reported and compared using X 2 -test or Fisher's exact test. OS, PFS, and GFRS were calculated using the Kaplan-Meier estimator. GvHD, RI, and NRM were estimated by cumulative incidence using the Gray and Fine method, with death from other causes defined as competitive events [9] . All calculations were done using SPPSS version 21.0 (IBM Corp. Armonk, NY) and R version 3.0.1 (the Comprehensive R Archive Network CRAN project). Differences between the two groups were statistically significant when p-value was under 0.05.
Three-year OS for all patients was 42% (95% confidence interval (CI): 28-56%), PFS was 34% (95% CI: 21-47%), GRFS was 26% (95% CI: 14-38%), RI was 37% (95% CI: 24-50%), and NRM was 25% (95% CI: 13-37%). Threeyear grade 2-4 acute GvHD was 29% (95% CI: 15-43%) and chronic GvHD was 27% (95% CI: 15-39%).
Three-year OS for partially T-cell-depleted patients and for non-partially T-cell-depleted ones was not different (48% [95% CI: 30-66%] vs. 34% [95% CI: 13-55%], pvalue 0.317; Fig. 1a There was no difference between partially T-celldepleted patients and non-partially T-cell-depleted patients for 3-year PFS (35% [95% CI: 18-52%] vs. 27% [95% CI: 7-47%], p-value 0.483; Fig. 1b) Finally, partial T-cell depletion had no significant impact on 3-year grade 2-4 aGVHD incidence when compared to the non-partially T-cell-depleted patients (26% [95% CI: 8-44%] vs. 31% [95% CI: 15-47%], p-value 0.656) and on 3-year cGVHD (26% [95% CI: 8-44%] vs. 28% [0-62%], p-value 0.637).
Our study established the feasibility of partial T-cell depletion in patients suffering from myelodysplastic syndrome without hampering relevant outcome such as OS, RI, PFS, and NRM. Moreover, there was a trend toward better GRFS for partially T-cell-depleted patients, a recent composite end point that includes significant negative events associated with allogeneic HSCT (risk of death, relapse, and GvHD), which is useful to determine the success of HSCT [10] . Even though partial T-cell depletion was previously reported to decrease aGVDH [7] , similar results were not observed in our cohort of MDS patients. It may be explained by the low number of patients, which reduced the power for such analysis. Because age at diagnosis of MDS is typically >65 years, strategies to reduce toxicities of transplantation are of first importance. In addition to reduced-intensity conditioning transplant, partial T-cell depletion could be an alternative to reduce GvHDassociated toxicities in elderly patients in complete remission at transplant time.
The main limitation of our study is the retrospective nature of our analysis and the limited number of patients in our cohort. Moreover, the chosen period span is long so patients' management could be quite different from one patient to another. Despite the fact that DRI was different between partially T-cell-depleted and non-partially T-celldepleted groups, there was no difference for the European Society for Blood and Marrow Transplantation score. Moreover, the lack of impact of partial T-cell depletion on OS was independent of DRI in multivariable analysis. In conclusion, we observe that partial T-cell depletion is feasible on patients undergoing HSCT for myelodysplastic syndrome and does not make the outcomes worse compared to non-partially T-cell-depleted patients (OS, PS, RI, NRM, and GRFS). Partial T-cell depletion needs to be prospectively investigated, especially in the field of elderly patients in complete remission at transplant time to see it it may reduce GvHD-associated toxicities.
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